8 ene 1998 año - FDA approves Dako's immunohistochemical assay, Herceptest, for detection of HER2 protein, the target of trastuzamab (Herceptin), a genetically engineered treatment for metastatic breast cancer.

Añadido al timeline:

23 sep 2017

0

0

310

New timeline

fecha: